ReviewTherapeutic advances in vaccines and immunotherapy2024
Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications.
Review in Therapeutic advances in vaccines and immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Formation and preliminary characterization of mercury-reactive immunoglobulin Y antibodies in laying hens using HgClVeterinary world · 2026Article
- Article
- Using IgY for diagnosis of respiratory infections: practical application in COVID-19.Future science OA · 2025Article
- Harnessing the Potential of IgY: A Creative Approach for Immunodiagnosis and Immunotherapy Against Viral Diseases of Animals.Current microbiology · 2025Review
- Egg Yolk Immunoglobulins (IgY) Purification, Activity Enhancement, and Potential Benefits for Human Health.Nutrients · 2025Review
- Latest Findings in Immunoglobulin Y Technologies and Applications.International journal of molecular sciences · 2025Review
- Development of IgY-Based Passive Immunization Against Tilapia Lake Virus: Development and In Vitro Neutralization Assays.Viruses · 2025Article
- Validation of six commercially available angiotensin II type 1 receptor antibodies.Acta biochimica et biophysica Sinica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their high specificity and scalability, Monoclonal IgY antibodies have emerged as a valuable alternative to traditional polyclonal IgY antibodies. This abstract provides an overview of the production and purification methods of monoclonal IgY antibodies, highlights their advantages over polyclonal IgY antibodies, and discusses their recent applications. Monoclonal recombinant IgY antibodies, in contrast to polyclonal IgY antibodies, offer several benefits. such as derived from a single B-cell clone, monoclonal antibodies exhibit superior specificity, ensuring consistent and reliable results. Furthermore, it explores the suitability of monoclonal IgY antibodies for low- and middle-income countries, considering their cost-effectiveness and accessibility. We also discussed future directions and challenges in using polyclonal IgY and monoclonal IgY antibodies. In conclusion, monoclonal IgY antibodies offer substantial advantages over polyclonal IgY antibodies regarding specificity, scalability, and consistent performance. Their recent applications in diagnostics, therapeutics, and research highlight their versatility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.